Erratum to: Targ Oncol

DOI 10.1007/s11523-012-0225-x

Some errors occurred in the publication of this article. It should read:

Conflict of interest Dr. Simona Grozinsky-Glasberg serves as an invited speaker for Novartis and IPSEN.

Financial disclosures for Professor Marianne Pavel: 1. Grant - Institution - Novartis 2. Consulting fee or honorarium - Novartis, Pfizer, IPSEN 3. Support for travel to meetings for the study or other purposes - Novartis 4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like -none 5. Payment for writing or reviewing the manuscript - None 6. Provision of writing assistance, medicines, equipment, or administrative support- None.

In Table 1:

Correct references:

US-52 [26]

RADIANT-2 [27]

RAMSETE [29]

Correct values for RADIANT-2 Median PFS: 16.4 vs 11.3 (placebo) instead of 16.3 vs 11.

In the following sentence, the reference has been changed to 25 rather than 22:

Thirdly, it remains unclear in which treatment line everolimus should be used. So far, data from RADIANT-3 trial [25] did not show any differences in efficacy depending on previous use of chemotherapy, compared to the use of everolimus in therapy-naive patients.

The below reference has been corrected:

27. Pavel ME, Hainsworth JD, Baudin E et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012